TABLE I.
Cohort Baseline Characteristics; n = 491
| Variables | Frequency (%) or mean ± SD |
|---|---|
| Baseline/start of ART | |
| Age (years) | 29.71 ± 7.71 |
| BMI (all regimens, kg/m2) | 26.52 ± 3.94 |
| BMI (all regimens, dichotomized) | |
| <25 | 183 (37.1%) |
| ≥25 | 308 (62.9%) |
| Anchors (all races) | |
| INSTI | 197 (40.1%) |
| NNRTI | 249 (50.6%) |
| PI | 45 (9.3%) |
| Race/ethnicity | |
| White | 157 (32.0%) |
| INSTI (% of Whites) | 67 (42.7%) |
| RAL | 18 |
| EVG | 20 |
| DTG | 29 |
| NNRTI (% of Whites) | 78 (49.7%) |
| EFV | 73 |
| RVP | 5 |
| PI (% of Whites) | 12 (7.6%) |
| DRV | 3 |
| ATV | 8 |
| LPV | 1 |
| African American | 215 (43.8%) |
| INSTI (% of African Americans) | 83 (38.6%) |
| RAL | 12 |
| EVG | 20 |
| DTG | 51 |
| NNRTI (% of African Americans) | 118 (54.9%) |
| EFV | 109 |
| RVP | 9 |
| PI (% of African Americans) | 14 (6.5%) |
| DRV | 3 |
| ATV | 11 |
| LPV | 0 |
| Other | 119 (24.2%) |
| INSTI | 47 (39.5%) |
| RAL | 8 |
| EVG | 16 |
| DTG | 23 |
| NNRTI | 53 (44.5%) |
| EFV | 41 |
| RVP | 12 |
| PI | 19 (16%) |
| DRV | 5 |
| ATV | 12 |
| LPV | 2 |
| Baseline CD4 count (cells/µL) | |
| <500 | 331 (67.3%) |
| ≥500 | 160 (32.7%) |
| Baseline viral load (c/mL) | |
| <100,000 | 383 (77.8%) |
| ≥100,000 | 108 (22.2%) |
| Time from HIV diagnosis to start of ART (years) | 1.52 ± 2.84 |
| One year after ART initiation | |
| BMI (all regimens) | 26.79 ± 3.89 |
| Two years after ART initiation | |
| BMI (all regimens) | 27.26 ± 4.14 |
Abbreviations: ATV, atazanavir; ART, antiretroviral therapy; BMI, body mass index; c/mL, copies per milliliter; cells/uL, cells per microliter; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; INSTI, integrase strand transfer inhibitor; LPV, lopinavir; NNRTI, non-nuceloside reverse transcriptase inhibitor; PI, protease inhibitor; RAL, raltegravir; RVP, rilpivirine; SD, standard deviation.